Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Clinical insights on “Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome (aHUS) switched from eculizumab”

Clinical insights on “Effectiveness and safety of ravulizumab for Japanese patients with atypical... Clinical and Experimental Nephrology https://doi.org/10.1007/s10157-025-02737-1 LE T TER TO  THE   EDITOR Clinical insights on “Eec ff tiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome (aHUS) switched from eculizumab” 1 1 2 3 4 Ali Karim  · FNU Rida  · Ekata Agnes Omoijuanfo  · Noor un nisa Irshad  · Abdul Karim Soomro  · Faqeer Muhammad Received: 5 July 2025 / Accepted: 7 July 2025 © The Author(s), under exclusive licence to Japanese Society of Nephrology 2025 To the Editor, comparison with previous data and might perhaps inflate the numerical effectiveness rate. The definition of outcomes We read with great interest the study of post-marketing sur- must be the same across trials of complement inhibitors for veillance (PMS) by Ito et al., titled “Effectiveness and safety longitudinal evaluation and comparison of treatments [4]. of ravulizumab for Japanese patients with atypical hemolytic Compared with future studies that would greatly benefit uremic syndrome (aHUS) switched from eculizumab” [1]. from controlled comparative design, standardized endpoints, These results provide much-needed real-world effectiveness and more demographically diverse populations, the clinical data for ravulizumab in this rare complement-mediated dis- value of ravulizumab would be better clarified in this regard. ease. The finding of a 97% event-free rate for TMA under - lines the promise of ravulizumab, particularly as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Experimental Nephrology Springer Journals

Clinical insights on “Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome (aHUS) switched from eculizumab”

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/clinical-insights-on-effectiveness-and-safety-of-ravulizumab-for-0OaFs3ZU40

References (4)

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Japanese Society of Nephrology 2025
ISSN
1342-1751
eISSN
1437-7799
DOI
10.1007/s10157-025-02737-1
Publisher site
See Article on Publisher Site

Abstract

Clinical and Experimental Nephrology https://doi.org/10.1007/s10157-025-02737-1 LE T TER TO  THE   EDITOR Clinical insights on “Eec ff tiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome (aHUS) switched from eculizumab” 1 1 2 3 4 Ali Karim  · FNU Rida  · Ekata Agnes Omoijuanfo  · Noor un nisa Irshad  · Abdul Karim Soomro  · Faqeer Muhammad Received: 5 July 2025 / Accepted: 7 July 2025 © The Author(s), under exclusive licence to Japanese Society of Nephrology 2025 To the Editor, comparison with previous data and might perhaps inflate the numerical effectiveness rate. The definition of outcomes We read with great interest the study of post-marketing sur- must be the same across trials of complement inhibitors for veillance (PMS) by Ito et al., titled “Effectiveness and safety longitudinal evaluation and comparison of treatments [4]. of ravulizumab for Japanese patients with atypical hemolytic Compared with future studies that would greatly benefit uremic syndrome (aHUS) switched from eculizumab” [1]. from controlled comparative design, standardized endpoints, These results provide much-needed real-world effectiveness and more demographically diverse populations, the clinical data for ravulizumab in this rare complement-mediated dis- value of ravulizumab would be better clarified in this regard. ease. The finding of a 97% event-free rate for TMA under - lines the promise of ravulizumab, particularly as

Journal

Clinical and Experimental Nephrology – Springer Journals

Published: Jul 15, 2025

There are no references for this article.